Rofaday
✅ Reduces lung inflammation
✅ Improves lung function
✅ Treats chronic bronchitis
✅ Decreases COPD exacerbations
✅ Enhances breathing capacity
Rofaday contains Roflumilast.
✓ Ιατρικά ελεγμένο από Morgan Ellis — Ερευνητής Φαρμακευτικής · 8 χρόνια εμπειρία · Τελευταία αναθεώρηση: Μάιος 2026
⚡ Quick Answer — What is Rofaday?
Rofaday περιέχει roflumilast 500 mcg, an oral selective phosphodiesterase-4 (PDE4) inhibitor taken once daily for severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis phenotype and frequent exacerbations. Roflumilast is anti-inflammatory rather than bronchodilator — it suppresses neutrophil and macrophage activation in airways, reducing exacerbation frequency by ~17% in landmark trials (M2-124, M2-125, REACT). It is added on top of optimal LAMA + LABA (± ICS) in patients with severe disease. Manufactured by Cipla.
📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.
Γιατί να παραγγείλετε από τη MedsBase
Τα γενόσημα φάρμακά μας προέρχονται από κατασκευαστές που πιστοποιούνται από την WHO-GMP και αποστέλλονται παγκοσμίως σε διακριτική, απλή συσκευασία — χωρίς όνομα φαρμάκου στο εξωτερικό του δέματος. Οι πληρωμές με κάρτα δρομολογούνται μέσω ρυθμισμένου επεξεργαστή (οι περιγραφές εκκαθάρισης περιλαμβάνουν ρυθμισμένο επεξεργαστή πληρωμών με κάρτα — ποτέ “MedsBase” ή οποιοδήποτε όνομα φαρμάκου). Γίνονται δεκτές και πληρωμές με κρυπτονομίσματα και τραπεζική μεταφορά SEPA. Κάθε παραγγελία καλύπτεται από την Πολιτική Επαναποστολής Εξασφαλίσεώς μας.
What Is Rofaday?
Rofaday is an oral PDE4 inhibitor for severe COPD. Roflumilast is the only PDE4 inhibitor licensed for COPD — sold internationally as Daxas (AstraZeneca) and Daliresp. It is a niche but well-evidenced add-on for the chronic bronchitis phenotype.
How Does Rofaday Work?
Phosphodiesterase-4 (PDE4) is the dominant cyclic AMP-degrading enzyme in inflammatory cells (neutrophils, macrophages, eosinophils, T-cells). Inhibiting PDE4 raises cyclic AMP in these cells, suppressing:
- Neutrophil chemotaxis and degranulation in airways
- Macrophage cytokine release (TNF-α, IL-8)
- Airway smooth-muscle proliferation and fibroblast activation
- Mucus hypersecretion and goblet-cell hyperplasia
The clinical result is a 15–17% reduction in COPD exacerbation rate when added to optimal inhaled therapy.
Χρήσεις και ενδείξεις
- Severe COPD (FEV1 <50% predicted) with chronic bronchitis and a history of exacerbations, on top of optimal LAMA + LABA (± ICS)
- Frequent exacerbator phenotype with persistent productive cough
Rofaday Dosage
| Patient | Δόση | Συχνότητα |
|---|---|---|
| Adults — start | 250 mcg for first 4 weeks | Once daily |
| Adults — maintenance | 500 mcg | Once daily, with or without food |
| Hepatic impairment | Avoid (Child-Pugh B/C) | — |
Side Effects of Rofaday
- Weight loss (averages 2–3 kg in trials — monitor; reverse if >5%)
- Diarrhoea, nausea (commonest reason for discontinuation; usually settles after first 2–4 weeks)
- Κεφαλαλγία
- Insomnia, anxiety
- Dyspepsia, abdominal pain
- Mood changes — depression, anxiety; rarely suicidal ideation (warning)
Serious — stop and seek help:
- Severe weight loss (>5% body weight)
- New or worsening depression, suicidal thoughts
- Severe persistent diarrhoea
- Σοβαρή αλλεργική αντίδραση
Προειδοποιήσεις και προφυλάξεις
- Mood and behaviour: screen for depression before starting; warn patients/families to report new mood symptoms.
- Weight loss: baseline and 3-monthly weight monitoring; if loss exceeds 5%, review or stop.
- Ηπατική δυσλειτουργία: avoid in Child-Pugh B and C.
- 4-week dose titration (250 mcg) reduces GI side effects and diarrhoea — most patients can then tolerate 500 mcg.
- Not a bronchodilator — does not replace LAMA, LABA, or ICS.
- Εγκυμοσύνη και θηλασμός: contraindicated.
- Drug interactions: CYP3A4 inducers (rifampicin) reduce levels — avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels — caution.
Αντενδείξεις
- Hypersensitivity to roflumilast
- Moderate-to-severe hepatic impairment (Child-Pugh B/C)
- Pregnancy
Αλληλεπιδράσεις Φαρμάκων
| Interacting drug | Αποτέλεσμα | Τι να κάνετε |
|---|---|---|
| CYP3A4 inducers (rifampicin, phenobarbital, phenytoin, carbamazepine) | Reduce roflumilast levels by 50% | Avoid |
| Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin) | Raise roflumilast levels — increase side effect risk | Caution; consider lower dose |
| Oral contraceptives containing gestodene | Modest increase in roflumilast levels | No dose adjustment usually needed |
Αποθήκευση
- Store below 25°C in a cool, dry place away from direct sunlight.
- Keep in original packaging until use to protect from moisture and light.
- Do not use after the expiry date printed on the strip.
- Keep out of reach of children.
Σχετικές Εναλλακτικές Λύσεις στο MedsBase
- Asthalin Inhaler — salbutamol reliever
- Budecort Inhaler — budesonide ICS preventer
- Foracort Inhaler — budesonide + formoterol ICS-LABA
- Tiova Inhaler — tiotropium LAMA for COPD
- Montair — montelukast LTRA tablet
Συχνές Ερωτήσεις
When is Rofaday added?
For severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and a history of frequent exacerbations on top of optimal LAMA + LABA (± ICS). Not for mild COPD or asthma.
Why must I start at 250 mcg?
A 4-week titration at 250 mcg dramatically reduces GI side effects (diarrhoea, nausea) — most patients can then move to the maintenance 500 mcg without intolerance.
How much does Rofaday reduce exacerbations?
About 15–17% reduction in moderate-to-severe COPD exacerbations in landmark trials (M2-124, M2-125, REACT). Most benefit seen in the chronic bronchitis with frequent exacerbator phenotype.
Will Rofaday make me lose weight?
Yes — average 2–3 kg in trials. Monitor weight at baseline and every 3 months. If loss exceeds 5%, review indication or stop.
What about mood changes?
Rare but reported. Screen for depression at baseline; counsel patient and family to report new mood symptoms, anxiety, or suicidal thoughts. Stop and review.
Is Rofaday a bronchodilator?
No — it is anti-inflammatory only. Continue your LAMA, LABA, and (where indicated) ICS inhalers.
Can I take Rofaday during pregnancy?
Contraindicated.
How does Rofaday compare to triple therapy?
Triple inhaler (Triohale) and Rofaday tackle COPD exacerbations through different mechanisms (bronchodilation + inflammation suppression vs PDE4-mediated anti-inflammation). Some patients benefit from both.
What are the most important drug interactions?
Rifampicin (and other CYP3A4 inducers) reduce Rofaday levels by half — avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels — caution.
Σχετικές Εναλλακτικές
Άλλα προϊόντα σε Χρόνιες Παθήσεις που οι πελάτες εξετάζουν επίσης:
More options in Asthma/COPD Treatment
Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.
| Ισχύς | 500 mcg |
|---|---|
| Ποσότητα | 30 δισκία, 60 δισκία, 90 δισκία, 180 δισκία |
Rofaday
Ερωτήσεις & Απαντήσεις
Rofaday
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές